サンプル依頼リスト カート
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：体外診断薬ビジネスの見通し、2025年（6銘柄）
市場調査レポート
商品コード
1642227

体外診断薬ビジネスの見通し、2025年（6銘柄）

In Vitro Diagnostics Business Outlook, 2025 (6 Issues)

出版日
ページ情報
英文
納期
即日から翌営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
体外診断薬ビジネスの見通し、2025年（6銘柄）
出版日: 2025年01月24日
発行: Kalorama Information
ページ情報: 英文
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

当レポートは隔月刊で年6回発行され、各号はIVD業界の異なるセグメントに特化し、市場データと予測、包括的な市場見通し、M&A活動、業界別、地域別動向などをまとめています。

体外診断用医薬品（IVD）部門は現代ヘルスケアの礎であり、病気の発見、健康状態のモニタリング、的確な治療判断のためのツールを臨床医に提供しています。

サンプル

ヘルスケアの進化に伴い、IVD市場は変革的な成長を遂げようとしています。糖尿病や心血管疾患などの慢性疾患の有病率が上昇し、COVID-19や新興亜種のような感染症による脅威が続く中、革新的な診断ソリューションに対する需要はかつてないほど高まっています。

独自の見識とデータを提供

  • 市場データと予測：市場データと予測：詳細な成長率、市場規模、市場シェアにより、新たな機会を特定
  • 包括的な市場展望：検査カテゴリーと企業プロファイルを網羅
  • M&A活動：M&A、パートナーシップ、提携に関する最新情報
  • 業界＆地域ウォッチ：地域や業界ごとの動向に基づいた戦略
  • ニュース分析：他では入手困難な独占的な情報を含む、重要なニュースやイベントに関する詳細なレポート

目次

市場分析：心臓バイオマーカー検査

  • 心臓バイオマーカーの概要

市場見通し

  • 地域市場
  • 会社概要
    • Abbott Diagnostics
    • Beckman Coulter
    • Siemens
  • ベンダー市場シェア

エグゼクティブニュースブリーフィング

財務ハイライト：BECTON DICKINSON、NATERA

診断市場の合併、買収、パートナーシップ契約

  • パートナーシップとコラボレーション
  • 合併と買収

業界別動向

  • 業界別動向：COVID-19/インフルエンザ最新情報

地域別動向

  • メキシコ

広範な企業発表

  • お知らせ
    • Rocheが質量分析システムのCEマークを取得
    • QIAGENが5つの標的症候群パネルのFDA認可を取得
    • Revvityが無料のテストステロン検査のFDA認可を取得
    • Spear BioがFDAの画期的デバイス指定を獲得
    • RocheがB細胞リンパ腫に対する初のISH検査の承認を発表
    • RocheがFDAから追加の認可を取得
目次
Product Code: 25-014KA

The in vitro diagnostics (IVD) sector stands as a cornerstone of modern healthcare, empowering clinicians with the tools to detect diseases, monitor health conditions, and guide precise treatment decisions.

SAMPLE VIEW

As healthcare evolves, the IVD market is poised for transformative growth. With the rising prevalence of chronic conditions such as diabetes and cardiovascular diseases, as well as ongoing threats from infectious diseases like COVID-19 and emerging variants, the demand for innovative diagnostic solutions has never been greater.

"In Vitro Diagnostics Business Outlook" is a bimonthly publication, delivering six issues annually, each dedicated to a different segment of the IVD industry. It provides exclusive insights and data, including:

  • Market Data and Forecasts: Detailed growth rates, market size, and market share to identify new opportunities.
  • Comprehensive Market View: Coverage of test categories and company profiles.
  • M&A Activities: Updates on mergers, acquisitions, partnerships, and collaborations.
  • Industry & Region Watch: Tailored strategies based on regional and industry-specific trends.
  • News Analysis: In-depth reporting on significant news and events, including exclusive information not readily available elsewhere.

TABLE OF CONTENTS

MARKET ANALYSIS: CARDIAC BIOMARKER TESTING

  • OVERVIEW OF CARDIAC BIOMARKERS
  • MARKET OUTLOOK
    • Figure: Cardiac Marker Testing Market by End User, 2024-2029 ($ million) (Lab-based, POC-based)
    • Table: Cardiac Marker Diagnostic Sales by End User, 2024-2029 ($ million) (Lab-based, POC-based)
    • Figure: Cardiac Marker Testing Market by End User and Total Value Over Time, 2019-2029 ($ million) (Lab-based, PoC-based)
    • Figure: Cardiac Marker Testing Market, by Marker, 2024 (% Share) (Troponin, BNP, CK-MB, Myoglobin, Other)
  • REGIONAL MARKET
    • Table: Cardiac Marker Test Sales Distribution by Global Region, 2024 (%) (Asia Pacific, Europe, North America, RoW)
  • COMPANY BRIEFS
    • Abbott Diagnostics
    • Beckman Coulter
    • Siemens
  • VENDOR MARKET SHARE
    • Figure: Market Share of Leading Vendors in the Cardiac Marker Segment, by Company, 2024 (%) (Abbott, Danaher, QuidelOrtho, Roche, Siemens, Others)

EXECUTIVE NEWS BRIEFING

  • BRIEFS
    • Senseera Closes $7.1 Million in Funding Round
    • Geneoscopy Closes Series C Funding
    • Oxford Cancer Analytics Raises $11 Million in Series A Funding
    • MiRXES Nabs $40 Million in Financing
    • Tethis Nabs Euro-15 Million Funding

FINANCIAL HIGHLIGHTS: BECTON DICKINSON, NATERA

  • BECTON DICKINSON REPORTS 4% REVENUE GROWTH IN FISCAL 2024
    • Table: Becton Dickinson Financial Review, by Business Segment, FY 2022-FY 2024 ($ million) (BD Medical, BD Life Sciences, BD Interventional)
    • Figure: Becton Dickinson Business Division Performance, by Business Segment, FY 2022-FY 2024 ($ million) (BD Medical, BD Life Sciences, BD Interventional)
    • Figure: BD Life Sciences Division, Segment Mix, FY 2020 vs. FY 2024 (%) (Integrated Diagnostic Solutions, Biosciences)
    • Figure: Becton Dickinson U.S./International Revenue Distribution, FY 2022-FY 2024 ($ million)
    • Figure: Becton Dickinson Revenue Distribution, by Region, FY 2024 (%) (EMEA, Greater Asia, United States, Other)
  • NATERA CONTINUES OVERALL GROWTH TREND WITH PRELIMINARY 2024 RESULTS, EXPECTING A 56% INCREASE OVER 2023
    • Figure: Natera Financial Overview by Quarter, Q1 2023-Q4 2024* ($ million)

DIAGNOSTIC MARKET MERGERS, ACQUISITIONS, AND PARTNERSHIP DEALS

  • PARTNERSHIPS AND COLLABORATIONS
  • MERGERS AND ACQUISITIONS
    • Table: Recent Diagnostic Market Mergers, Acquisitions, and Partnership Deals, Dec. 2023-Jan. 2025

INDUSTRY WATCH

  • INDUSTRY WATCH COVID-19/FLU UPDATE

REGION WATCH

  • MEXICO
    • Figure: Mexico GDP, GDP (PPP), and Health Spending, 1990-2020, estimated 2025 ($ billion)
    • Figure: Mexico IVD Market Sales Trends, by Broad IVD Segment, 2016-2024 ($ million) (Clinical Chemistry, Hematology, and Coagulation; Histology; Immunoassays; Microbiology; POC; Others)

BROAD-BASED COMPANY ANNOUNCEMENTS

  • ANNOUNCEMENTS
    • Roche Secures CE Marking for Mass Spec System
    • QIAGEN Receives FDA Clearance for Five-Target Syndromic Panel
    • Revvity Secures FDA Clearance for Free Testosterone Test
    • Spear Bio Secures FDA Breakthrough Device Designation
    • Roche Announces Clearance of First ISH Test B-cell Lymphoma
    • Roche Receives Additional FDA Clearance

MARKET ANALYSIS: INFECTIOUS DISEASE TESTING

  • OVERVIEW OF INFECTIOUS DISEASE TESTING
  • MARKET OUTLOOK
    • Table 1: Global Infectious Disease Testing Market Revenue, by Segment, 2024-2029 ($ million) [Lab-based Immunoassays, Lab-based Molecular, Point-of-Care Tests]
    • Figure 1: Global Infectious Disease Testing Market, by Segment, 2019-2029 ($ million) [Lab-based Immunoassays, Lab-based Molecular, Point-of-Care Tests]
    • Figure 2: Global Infectious Disease Testing Market, Change in Market Performance by Segment, 2023-2024 [Blood Bank Screening, COVID-19, HAIs/Sepsis, Hepatitis, HIV, Respiratory (excl. COVID), Others]
    • Figure 3: Global Infectious Disease Testing Market, by Analyte Target, Distribution of Sales, 2024 [Blood Bank Screening, COVID-19, HAIs/Sepsis, Hepatitis, HIV, Respiratory (excl. COVID), Others]
  • REGIONAL MARKET
    • Table 2: Infectious Disease Testing, Distribution by Global Region, 2024 [North America, Europe, Asia Pacific, RoW]
  • COMPANY BRIEFS
    • Roche
    • Abbott
    • Danaher
    • Other Participants

EXECUTIVE NEWS BRIEFING

  • BRIEFINGS
  • Dxcover Limited Raises New Capital
  • Cubit Diagnostics Awarded NIH Funding
  • CARB-X Funds AstraDx's Neonatal Sepsis Rapid Test
  • Freenome Raises Additional $254 Million
  • Renovaro Secures $15 Million in New Capital
  • Ataraxis AI Secures $20.4 Million in Funding
  • MSInsight Nabs €1.6 Million Seed Funding
  • C2N Diagnostics Receives $10 Million Investment

FINANCIAL HIGHLIGHTS: GUARDANT HEALTH, ROCHE

  • GUARDANT REPORTS STRONG DEMAND – INCREASING REVENUES +31% OVER PREVIOUS YEAR
    • Figure 4: Guardant Health Test Volume, by Segment and Total, Quarterly Q1 2023 through Q4 2024 [Biopharmaceutical Customers, Clinical Customers]
    • Table 3: Guardant Health, by Group Business Revenue, FY 2023 vs FY 2024 ($ million) [Clinical Precision Oncology Testing, Development Services and Other]
    • Figure 5: Guardant Health, by Group Business, FY 2023 vs FY 2024 ($ million) [Clinical Precision Oncology Testing, Development Services and Other]
    • Figure 6: Guardant Health Revenue Performance, by Geographic Region, FY 2023 vs FY 2024 ($ million) [United States, International]
  • ROCHE DIAGNOSTIC SALES GROW 4% CER IN 2024 – SUPPORTED BY DEMAND FOR IMMUNODIAGNOSTICS, PATHOLOGY, AND MOLECULAR SOLUTIONS
    • Table 4: Roche, by Group Business, 2024 (CHF MN) [Diagnostic Division, Pharmaceutical Division]
    • Figure 7: Roche Diagnostics, 2024 Product Sales Breakdown, 2024 (CHF MN) [Core Lab, Molecular, Pathology Lab, Point-of-Care]
    • Figure 8: Roche Diagnostic, Segment Distribution, 2024 (%) [Core Lab, Molecular, Pathology Lab, Point-of-Care]
    • Table 5: Roche Diagnostics Division Sales, by Region, 2024 (CHF MN)

DIAGNOSTIC MARKET MERGERS, ACQUISITIONS, AND PARTNERSHIP DEALS

  • MERGERS AND ACQUISITIONS
    • Table 6: Recent Diagnostic Market Mergers, Acquisitions, and Partnership Deals, Dec. 2024-March 2025
  • PARTNERSHIPS AND COLLABORATIONS

INDUSTRY WATCH

  • INDUSTRY WATCH COVID-19/FLU UPDATE

REGION WATCH

  • BRAZIL
    • Figure 9: Brazil Short-Term GDP Growth and Inflation Change, 2022-2024, 2025-2026 Projected (%)
    • Figure 10: Brazil General Government Gross Debt as a Percent of GDP, 2000-2020 and 2025 projected (%)
    • Figure 11: Brazil IVD Market Distribution of Sales, by IVD Segment, 2024 (%)

BROAD-BASED COMPANY ANNOUNCEMENTS

  • ANNOUNCEMENTS
    • AliveDx Nabs CE Mark for Expanded Autoimmune Menu
    • Beckman Coulter Received FDA Breakthrough Device Designation
    • Beckton Dickinson to Spin Off Bioscience and Diagnostic Business
    • GRAIL Provides Galleri Multi-Cancer Early Detection Test Through Quest
    • Molecular Instruments RNA-ISH Enables Breakthrough LDT
    • Roche Snags FDA Clearance for Preeclampsia Test
    • CytoChip Receives FDA Clearance and CLIA Waiver
    • Cicero Diagnostics Unveiled Endometriosis Detection LDT
    • bioMérieux Secures FDA Clearance for BIOFIRE FILMARRAY GI Panel
    • Beckman Coulter Gains Clearance for its DxC 500i